ABSTRACT
BACKGROUND AND OBJECTIVE: Topical and intralesional (IL) treatments may be considered the first-line therapy in patients with hidradenitis suppurativa (HS); however, the evidence supporting their use is limited. The aim of our review is to evaluate the efficacy and safety profile of topical and IL treatments in patients with HS. MATERIALS AND METHODS: We designed a systematic review of the current medical literature available following the PICO(T) method. And including all types of studies (Study type [T]) of individuals with HS of any sex, age, and ethnicity (Population [P]) who received any topical or IL treatment for HS (Intervention [I]) compared to placebo, other treatments, or no treatment at all (Comparator [C]), and reported efficacy and/or safety outcomes (Outcomes [O]). Two outcomes were defined: quality of life and the no. of patients with, at least, one adverse event. The search was conducted in the Cochrane Library, MEDLINE, and Embase databases; study selection was performed based on pre-defined criteria. The risk of bias was determined in each study. RESULTS: We obtained a total of 11,363 references, 31 of which met the inclusion criteria. These studies included 1143 patients with HS, 62% of whom were women. A total of 10, 8, 6, 2, and 5 studies, respectively, evaluated the use of photodynamic therapy (PDT), glucocorticoids, resorcinol, topical antibiotics, and other interventions. Most articles were case series (n=25), with only five randomized clinical trials (RCTs) and one cohort study. RCTs showed improvement in disease activity with topical clindamycin and botulinum toxin (BTX) vs placebo, and PDT with methylene blue (MB) niosomal vs free MB; however, intralesional triamcinolone acetonide was not superior to placebo. The risk of bias was low in three RCTs and high in two RCTs. CONCLUSION: The quality of evidence supporting the use of topical, or IL treatments is low. However, it supports the use of topical clindamycin, PDT, and BTX. Well-designed RCTs with standardized outcomes and homogeneous populations of patients and lesions are needed to support decision-making in the routine clinical practice.
Subject(s)
Administration, Topical , Hidradenitis Suppurativa , Injections, Intralesional , Hidradenitis Suppurativa/drug therapy , Humans , Photochemotherapy/methods , Treatment Outcome , Female , Randomized Controlled Trials as Topic , MaleABSTRACT
BACKGROUND: Combinations of topical (TT) and biological therapies (BT) are a common thing in the routine clinical practice. However, the scientific medical literature on how TT is, actually, used after the initiation of BT is scarce, particularly in combination with anti-IL17, or anti-IL23. OBJECTIVES: To describe the frequency of the concomitant use of TT + BT at baseline and after a 6-month course of several drugs (anti-IL17, ustekinumab, and anti-IL23). Our secondary endpoints are to describe the type of topical therapy used, compare the frequency of use of TT among the different groups of BT, describe the survival of topical therapy in these patients, and identify the factors that can impact the use or discontinuation of topical therapy in these patients (clinical response, quality of life, type of drug, etc.). MATERIALS AND METHODS: This was a retrospective, observational, and single-center study of patients with moderate-to-severe psoriasis treated with anti-IL17 (secukinumab, ixekizumab), anti-IL17R (brodalumab), ustekinumab, and guselkumab from January 2015 through December 2020. RESULTS: We included a total of 138 patients. When treatment started, 82.7% were on TT (55% daily), and after 6 months, 86.6% had discontinued TT. Regarding the analysis by type of drug, at 6 months, we found that 100% of the patients with BRO had discontinued topical treatment. We did not find any significant differences in the frequency of use of TT based on the BT used during the 6-month course of treatment. The estimated mean course of TT was 4.3 months (SD, 6.7). Also, the estimated mean course of TT was significantly shorter in the group of patients who achieved PASI100 (2.8 months vs. 8.1 months). CONCLUSIONS: In our cohort, we saw a significant decrease in the frequency of use of TT at 6 months after starting BT in the routine clinical practice. This reduction occurred earlier in patients who improved their objective clinical response and quality of life.
Subject(s)
Interleukin-17 , Interleukin-23 , Psoriasis , Severity of Illness Index , Humans , Psoriasis/drug therapy , Retrospective Studies , Male , Interleukin-23/antagonists & inhibitors , Female , Interleukin-17/antagonists & inhibitors , Middle Aged , Ustekinumab/therapeutic use , Ustekinumab/administration & dosage , Adult , Drug Therapy, Combination , Quality of Life , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Administration, Topical , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosageABSTRACT
BACKGROUND AND OBJECTIVE: Topical and intralesional (IL) treatments may be considered the first-line therapy in patients with hidradenitis suppurativa (HS); however, the evidence supporting their use is limited. The aim of our review is to evaluate the efficacy and safety profile of topical and IL treatments in patients with HS. MATERIALS AND METHODS: We designed a systematic review of the current medical literature available following the PICO(T) method. And including all types of studies (Study type [T]) of individuals with HS of any sex, age, and ethnicity (Population [P]) who received any topical or IL treatment for HS (Intervention [I]) compared to placebo, other treatments, or no treatment at all (Comparator [C]), and reported efficacy and/or safety outcomes (Outcomes [O]). Two outcomes were defined: quality of life and the no. of patients with, at least, one adverse event. The search was conducted in the Cochrane Library, MEDLINE, and EMBASE databases; study selection was performed based on pre-defined criteria. The risk of bias was determined in each study. RESULTS: We obtained a total of 11,363 references, 31 of which met the inclusion criteria. These studies included 1143 patients with HS, 62% of whom were women. A total of 10, 8, 6, 2, and 5 studies, respectively, evaluated the use of photodynamic therapy (PDT), glucocorticoids, resorcinol, topical antibiotics, and other interventions. Most articles were case series (n=25), with only five randomized clinical trials (RCTs) and one cohort study. RCTs showed improvement in disease activity with topical clindamycin and botulinum toxin (BTX) vs placebo, and PDT with methylene blue (MB) niosomal vs free MB; however, intralesional triamcinolone acetonide was not superior to placebo. The risk of bias was low in three RCTs and high in two RCTs. CONCLUSION: The quality of evidence supporting the use of topical, or IL treatments is low. However, it supports the use of topical clindamycin, PDT, and BTX. Well-designed RCTs with standardized outcomes and homogeneous populations of patients and lesions are needed to support decision-making in the routine clinical practice.
Subject(s)
Administration, Topical , Hidradenitis Suppurativa , Injections, Intralesional , Humans , Hidradenitis Suppurativa/drug therapy , Photochemotherapy/methods , Randomized Controlled Trials as Topic , Treatment OutcomeABSTRACT
Localized neuropathic pain (LNP) is of peripheral origin and is characterized by circumscribed areas of pain with abnormal skin sensitivity or spontaneous symptoms that are characteristic of neuropathic pain, e.g., burning pain. It should be noted that LNP is confined to a specific area no larger than a letter size sheet of paper. LNP accounts for 60 % of neuropathic pain syndromes. There is no single etiology of LNP. The diagnostic approach is similar to that for other neuropathic pain conditions. General diagnostic tools are used to assess clinical features. So far, there are no specific guidelines for the management of LNP; for this reason, guidelines for general neuropathic pain are used. Topical treatments are included as part of second-line strategies in the Canadian Pain Society guidelines. Despite the lack of guidelines, 5 % lidocaine patches and 8 % capsaicin patches have been proven effective in LNP models.
El dolor neuropático localizado (DNL) es de origen periférico y se caracteriza por áreas circunscritas de dolor con sensibilidad anormal de la piel o síntomas espontáneos característicos de dolor neuropático, por ejemplo, dolor urente. Se debe resaltar que el DNL está confinado a un área específica no mayor a una hoja de papel tamaño carta. El DNL representa 60 % de las condiciones de dolor neuropático. No existe una única etiología. El abordaje diagnóstico es similar al de otros síndromes dolorosos neuropáticos. Se utilizan herramientas diagnósticas generales para evaluar las características clínicas. En la actualidad no existen guías específicas de manejo del DNL, por lo que se utilizan las guías para dolor neuropático en general. En las guías de la Sociedad Canadiense de Dolor se incluyen los tratamientos tópicos como parte de las estrategias de segunda línea. Pese a la falta de guías, los parches de lidocaína a 5 % y los parches de capsaicina a 8 % han demostrado ser efectivos en modelos de DNL.
Subject(s)
Neuralgia , Canada , Humans , Neuralgia/diagnosis , Neuralgia/etiology , SyndromeABSTRACT
Resumen El dolor neuropático localizado (DNL) es de origen periférico y se caracteriza por áreas circunscritas de dolor con sensibilidad anormal de la piel o síntomas espontáneos característicos de dolor neuropático, por ejemplo, dolor urente. Se debe resaltar que el DNL está confinado a un área específica no mayor a una hoja de papel tamaño carta. El DNL representa 60 % de las condiciones de dolor neuropático. No existe una única etiología. El abordaje diagnóstico es similar al de otros síndromes dolorosos neuropáticos. Se utilizan herramientas diagnósticas generales para evaluar las características clínicas. En la actualidad no existen guías específicas de manejo del DNL, por lo que se utilizan las guías para dolor neuropático en general. En las guías de la Sociedad Canadiense de Dolor se incluyen los tratamientos tópicos como parte de las estrategias de segunda línea. Pese a la falta de guías, los parches de lidocaína a 5 % y los parches de capsaicina a 8 % han demostrado ser efectivos en modelos de DNL.
Abstract Localized neuropathic pain (LNP) is of peripheral origin and is characterized by circumscribed areas of pain with abnormal skin sensitivity or spontaneous symptoms that are characteristic of neuropathic pain, e.g. burning pain. It should be noted that LNP is confined to a specific area no larger than a letter size sheet of paper. LNP accounts for 60 % of neuropathic pain conditions. There is no single etiology of LNP. The diagnostic approach is similar to that for other neuropathic pain syndromes. General diagnostic tools are used to assess clinical features. So far, there are no specific guidelines for the management of LNP; for this reason, guidelines for general neuropathic pain are used. Topical treatments are included as part of second-line strategies in the Canadian Pain Society guidelines. Despite the lack of guidelines, 5 % lidocaine patches and 8 % capsaicin patches have been proven effective in LNP models.
Subject(s)
Humans , Neuralgia/diagnosis , Neuralgia/etiology , Syndrome , CanadaABSTRACT
En este monográfico se realiza una revisión de todos los aspectos relacionados con la artrosis para poder ofrecer al/la paciente el manejo más óptimo a la luz de la bibliografía disponible en el momento de redacción del mismo. En este artículo en concreto realizamos una revisión bibliográfica del tratamiento farmacológico de la artrosis con paracetamol, antinflamatorios no esteroideos clásicos (AINE) e inhibidores selectivos de la ciclooxigenasa tipo 2 (COXIB). Actualizamos los aspectos que más nos interesan desde un punto de vista clínico: eficacia, seguridad, comparativa dentro de estas opciones y con el resto de alternativas (intervencionistas u otras farmacológicas), para poder decidir los perfiles de pacientes en los que puede estar indicado este tipo de opciones farmacológicas, el momento evolutivo de su enfermedad o incluso el tiempo de mantenimiento de este tipo de fármacos. Para ello hemos realizado una revisión bibliográfica de los estudios que evalúan el efecto de estos fármacos analgésicos en la artrosis mediante una búsqueda electrónica utilizando Google Scholar, Medline/PubMed y la base de datos Cochrane de revisiones sistemáticas con el fin de recopilar la literatura disponible entre los años 2000 y 2020.(AU)
In this monograph, a review of all aspects related to osteoarthritis is carried out in order to offer the patient with osteoarthritis the most optimal management in light of the bibliography available at the time of writing. In this specific article, we made a bibliographic review of the pharmacological treatment of osteoarthritis with paracetamol, classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase type 2 inhibitors (COXIBS). We update the aspects that interest us most from a clinical point of view: efficacy, safety, comparison within these options and with the rest of the alternatives (interventional or other pharmacological) for being able to decide the patient profiles in which this type is indicated of pharmacological options, the evolutionary moment of the disease or even the maintenance time of this type of drug. For reaching our objective, we have carried out a bibliographic review of the studies evaluating the effect of these analgesic drugs in osteoarthritis with an electronic search using Google Scholar, Medline/PubMed and the Cochrane database of systematic reviews to compile the available literature between the years 2000 and 2020.(AU)
Subject(s)
Humans , Male , Female , Pain Management/methods , Drug Therapy , Osteoarthritis/drug therapy , Acetaminophen/administration & dosage , Cyclooxygenase 2 Inhibitors , Anti-Inflammatory Agents, Non-Steroidal , Pain/drug therapy , Analgesics/administration & dosage , Treatment Outcome , Drug-Related Side Effects and Adverse ReactionsABSTRACT
Atopic dermatitis is the most common inflammatory skin disease and up to 20% of cases can be classified as moderate to severe. Our understanding of the pathogenesis of this disease has improved in recent years. The process is primarily driven by the Th2 pathway, but with significant contributions from the Th22 pathway, the Th1 and Th17 axes, epidermal barrier dysfunction, pruritus, and JAK/STAT signaling. Advances in our understanding of the pathogenesis of atopic dermatitis have led to the development of new systemic treatments. Of particular note are biologic agents targeting IL-4 and IL-13 (e. g., dupilumab, tralokinumab, and lebrikizumab) and small molecules, such as JAK inhibitors (e. g., baricitinib, upadacitinib, and abrocitinib). Novel topical treatments include phosphodiesterase 4 and JAK/STAT inhibitors. In this article, we review the main advances in the treatment of atopic dermatitis. Characterization of clinical and molecular phenotypes with a key pathogenic role is essential for driving these advances.
Subject(s)
Dermatitis, Atopic , Eczema , Janus Kinase Inhibitors , Dermatitis, Atopic/drug therapy , Humans , Interleukin-13 , Janus Kinase Inhibitors/therapeutic use , PruritusABSTRACT
Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are given on the correct application of topical treatment.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Colitis, Ulcerative/drug therapy , Glucocorticoids/administration & dosage , Mesalamine/administration & dosage , Administration, Topical , HumansABSTRACT
Topical agents are the first-line treatment for mild and moderate psoriasis, but factors such as frequency of administration, organoleptic properties, and the limited short term results can reduce treatment adherence and effectiveness. Innovations in topical treatments are linked not only to the discovery of new molecules, but also to the reformulation of existing active ingredients based on improvements to administration, organoleptic properties, bioavailability, and ease of use. Calcipotriol and betamethasone dipropionate aerosol foam is a new formulation in which the active ingredients are dissolved in a mixture of volatile propellants that evaporate quickly, leaving a supersaturated solution of calcipotriol and betamethasone dipropionate that enhances penetration into the epidermis. In this article, we take a look at the new calcipotriol and betamethasone dipropionate aerosol formulation and briefly review the main evidence supporting the use of topical treatments for psoriasis.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Betamethasone/analogs & derivatives , Calcitriol/analogs & derivatives , Dermatologic Agents/administration & dosage , Psoriasis/drug therapy , Administration, Topical , Aerosols , Betamethasone/administration & dosage , Calcitriol/administration & dosage , Drug Therapy, Combination , HumansABSTRACT
Resumen Introducción: La diversidad de las formas clínicas de la leishmaniasis del Nuevo Mundo (desde formas cutáneas localizadas a diseminadas o formas mucosas) causada por especies del subgénero Viannia podría inferir en la eficacia de los tratamientos tópicos. El objetivo del presente trabajo fue determinar las características de la leishmaniasis cutánea producida por infecciones con Leishmania (V.) braziliensis y L.(V.) panamensis en ratones BALB/c y la eficacia de un mismo tratamiento tópico. Materiales y métodos: Después de la infección con cada una de las especies se realizó seguimiento de las lesiones determinando su tamaño (mm ) y características macroscópicas, cada siete días por 150 días. Las características histopatológicas (en lesiones y órganos) fueron determinadas 70, 106 y 150 días post-infección y la eficacia de un tratamiento tópico (cura de lesión y parasitológica) fue determinada después del tratamiento con un gel de miltefosina aplicado una vez al día por 20 días sobre las lesiones. Resultados: Se observó un aumento del tamaño de las lesiones en ambos grupos de ratones, sin embargo, un mayor tamaño de las lesiones e intensidad de la respuesta inflamatoria con menos alteraciones epidérmicas fue encontrada en los ratones infectados con L. (V.) braziliensis. En ningún grupo se encontraron parásitos en órganos (nódulos, bazo e hígado) ni diferencias en la efectividad del tratamiento tópico utilizado. Conclusión: La eficacia del tratamiento tópico utilizado no fue afectada por las diferencias macro y microscópicas encontradas en la leishmaniasis producida por las dos especies de Leishmania evaluadas.
Abstract Introduction: The efficacy of topical treatments could be affected by the diversity of clinical forms (localized or disseminated cutaneous forms, mucosal forms) of New World-leishmaniasis caused by species of Leishmania from the subgenus Viannia. The aim of this study was to determine the cutaneous leishmaniasis features produced after infection with Leishmania (V.) braziliensis and L. (V.) panamensis in BALB/c mice and to determine the efficacy of one topical treatment. Materials and methods: Cutaneous leishmaniasis lesions were followed up after infection determining their lesion-size (mm2) and other macroscopic characteristics every 7 days for 150 days. Histopathological patterns (in lesions and organs) were determined 70, 106 and 150 days post-infection and the efficacy (lesion and parasitological cure) of miltefosine gel applied topical once a day for 20 days was determined. Results: An increase of size-lesions was observed in both groups of mice, however, a higher lesion- size and inflammatory response but lower epidermal changes were observed in L. (V.) braziliensis compared with L. (V.) panamensis infected ones. No parasites were observed in organs (nodules, spleen and liver) and no differences were observed in the effectiveness of the used topical treatment. Conclusion: The efficacy of the topical treatment used was not affected by the macro and microscopic differences produced after infection by the two Leishmania species evaluated.
Subject(s)
Animals , Leishmania braziliensis , Leishmania guyanensis , Mice, Inbred BALB C , Anti-Infective Agents, LocalABSTRACT
Human immunodeficiency virus (HIV) prevalence is increasing worldwide as people on antiretroviral therapy are living longer. These patients are often susceptible to debilitating inflammatory disorders that are frequently refractory to standard treatment. Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection. In this population, psoriasis tends to be more severe, to have atypical presentations and higher failure rates with the usual prescribed treatments. Management of moderate and severe HIV-associated psoriasis is challenging. Systemic conventional and biologic agents may be considered, but patients should be carefully followed up for potential adverse events, like opportunist infections, and regular monitoring of CD4 counts and HIV viral loads.
Subject(s)
HIV Infections/complications , Psoriasis/complications , Adrenal Cortex Hormones/therapeutic use , Biological Therapy , Contraindications, Drug , Diagnosis, Differential , Disease Management , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Phototherapy , Prevalence , Pseudolymphoma/diagnosis , Psoriasis/epidemiology , Psoriasis/immunology , Psoriasis/therapy , Scabies/diagnosis , Syphilis/diagnosis , Syphilis, Cutaneous/diagnosis , Thalidomide/analogs & derivatives , Thalidomide/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
BACKGROUND: Ulcerative proctitis (UP) presents distinctive clinical characteristics, outcomes and therapeutic approaches as compared to left-sided and extensive ulcerative colitis (UC). AIM: To describe the current therapeutic requirements and clinical outcomes in patients with active UP. METHODS: Retrospective observational study conducted in a referral IBD centre. Patients with UP in follow-up between 1989 and 2014 were included. The clinical characteristics, as well as the different treatments and drug formulations administered to treat flares, were recorded. RESULTS: Out of 687 UC patients, 101 patients (15%) with UP were included. Median follow-up was 8 years (IQR 3-14) and 49% of patients presented disease activity during the study period. Topical mesalazine monotherapy (90%) was the most commonly administered treatment for disease activity (mostly as suppositories), followed by topical steroids (47%) and oral mesalazine (56%) in monotherapy or combination therapy. Only 14% and 16% of patients required oral prednisone and beclomethasone, respectively. CONCLUSIONS: In clinical practice, active UP presents mostly favourable outcomes. Mesalazine suppositories are by far the most used treatment for these patients.
Subject(s)
Colitis, Ulcerative/drug therapy , Proctitis/drug therapy , Adult , Colitis, Ulcerative/complications , Female , Humans , Male , Middle Aged , Proctitis/complications , Retrospective Studies , Treatment OutcomeABSTRACT
CLINICAL CASES: The cases are presented of two patients with periocular basal cell carcinoma of the eyelid who received topical imiquimod 5%, with a good response. Both had a functional state that contraindicated surgical treatment. CONCLUSION: Imiquimod cream 5% was shown to be an effective alternative to surgical treatment of periocular basal cell carcinoma, especially in those cases where surgery is not possible.
Subject(s)
Aminoquinolines/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Eyelid Neoplasms/drug therapy , Acquired Immunodeficiency Syndrome/complications , Aminoquinolines/adverse effects , Antineoplastic Agents/adverse effects , Contraindications, Procedure , HIV-Associated Lipodystrophy Syndrome/complications , Humans , Imiquimod , Male , Middle Aged , Plastic Surgery Procedures , Remission Induction , Skin Ulcer/chemically induced , Surgical FlapsABSTRACT
La Dermatitis Atópica es una dermatosis inflamatoria crónica y pruriginosa, muy frecuente en todo el mundo. En esta actualización revisamos aspectos históricos que consideramos relevantes para el entendimiento de la patología, buscando consenso en los criterios diagnósticos, que cada vez son más concordantes entre las diferentes escuelas y por otra parte revisamos la importancia de la terapia tópica y sus novedades.
Atopic dermatitis (AD) A is a chronic, pruritic, inflammatory dermatosis, very common in all parts of the world. In this update we review the historical aspects that we consider relevant for the understanding of the pathology, seeking consensus in the great variety of diagnosis criteria that are every day more similar among different dermatological groups. We also review the importance of topical therapy and the new findings.
Subject(s)
Humans , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/therapyABSTRACT
Psoriasis is a complex inflammatory disease, and in women the incidence is high in child-bearing years. Treatment during pregnancy presents genuine challenges since management requires adequate assessment of the extent of disease, comorbidity, and potential risk to the fetus. Scientific evidence is scarce on the effects that certain drugs have on fetal development given the ethical concerns about enrolling pregnant women in clinical trials. This review presents up-to-date information on the course of psoriasis during gestation and discusses associated conditions and the therapeutic protocols recommended for use during pregnancy.
Subject(s)
Pregnancy Complications , Psoriasis , Female , Humans , Practice Guidelines as Topic , Pregnancy , Pregnancy Complications/drug therapy , Psoriasis/drug therapy , Risk FactorsABSTRACT
Introducción: La obstrucción del lumen de las colleras es un evento infrecuente, pero que anula la efectividad del dispositivo en la ventilación del oído medio. Existen múltiples opciones de tratamiento tópico para esta situación clínica, sin embargo, los reportes en la literatura al respecto presentan resultados contradictorios. Objetivos: Analizar la efectividad de distintos tratamientos tópicos para destapar una collera ocluida con coágulo de sangre. Material y método: Modelo experimental ex vivo, 184 tubos de ventilación obstruidos con coágulo de sangre. Tratamiento tópico, 8 grupos experimentales (agua oxigenada 3 por ciento, ácido acético 5 por ciento, ciprofloxacino 0,3 por ciento, vinagre de mesa, heparina, mezcla de H2O2/acetato 1:1, suero fisiológico 0.9 por ciento) y 2 grupos control (sin tratamiento). Revisión de permeabilidad de lumen de colleras a los 3, 7 y 10 días. Resultados: El agua oxigenada (H2O2) resulta ser el tratamiento más efectivo (88 por ciento y 92 por ciento de efectividad a los 7 y 10 días). Ciprofloxacino, vinagre de mesa, suero fisiológico y heparina son inefectivos, sin diferencias significativas con grupo control. Ciprofloxacino y suero fisiológico sedimentan más, e incluso tapan colleras previamente permeables. Conclusiones: H2O2 es un tratamiento seguro, efectivo y económico para destapar colleras obstruidas con coágulos de sangre.
Introduction: Blocked tympanostomy tubes (TT) are an uncommon event, but avoids the effectiveness of this device in middle ear ventilation. Many topical treatment options are available for this clinical situation, however, reports in literature show conflicting results. Aim: Analyze the effectiveness of various topical treatments to open blood clot blocked TT. Material and Method: Ex vivo experimental model. 184 blood clot blocked TT. Topical treatment, 8 experimental groups (3 percent hydrogen peroxide, 5 percent acetic acid, 0,3 percent ciprofloxacin, vinegar, heparin, mixture 1:1 H2O2/acetate, 0.9 percent saline) and 2 control group (no treatment). Review of tube permeability at 3, 7 and 10 days of treatment. Results: H2O2 is the most effective treatment (88 percent & 92 percent effectiveness at 7 & 10 days). Ciprofloxacin, vinegar, saline and heparin are ineffective, with no statistical differences with control group. Ciprofloxacin and saline even blocked previously opened TT. Conclusions: H2O2 is a safe, effective and economic treatment to clear blood clot blocked TT.
